IL6 and ovarian carcinoma: Accordingly, high IL-6 levels in ascites predicted a shorter PFS in patients with EOC, and the therapeutic potential of targeting IL-6 and downstream signaling has been shown in mouse models of ovarian cancer [11, 36, 37].